Bispecific antibody therapy is an advanced, targeted treatment designed to help your immune system detect and destroy cancer cells.
This innovative therapy works by guiding your T cells—the immune system’s defenders—directly to cancer cells. Treatment is delivered through an infusion or injection. Once inside the body, the bispecific antibody binds to two targets: one side attaches to the cancer cell, and the other connects with the T cell. This connection brings them together, triggering a more focused and powerful immune response.
At Missouri Cancer Associates, bispecific therapy is administered in our outpatient infusion center. Our team uses a step-up dosing approach, gradually increasing medication during initial treatments to minimize side effects. After this phase, therapy continues at scheduled intervals or as maintenance treatment.
Because bispecific antibodies directly link immune cells to cancer cells, this therapy can be effective for patients whose cancer has resisted other treatments. Clinical studies show improved outcomes for several cancer types, including small cell lung cancer and blood cancers.
Bispecific antibody therapy is available for patients diagnosed with:
- Acute Lymphoblastic Leukemia
- Uveal Melanoma
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Multiple Myeloma
- Extensive-Stage Small Cell Lung Cancer
Our expert oncology team will work with you to determine if bispecific antibody therapy is right for your treatment plan.
For more information or to schedule a consultation, call Missouri Cancer Associates at (573) 874-7800.